Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Baricitinib Commercial vs Phase 2 Tablets and Food Effect in Healthy Japanese Subjects
NCT02263911Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2014
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of baricitinib in rheumatoid arthritis (RA) (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero to Infinity at Day 1, Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration at Day 1 and 1 more. Started Nov 2014; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02263911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263911.